الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Summary Neonatal jaundice is one of the commonest clinical signs in neonates, which generally reflects a regular transitional phenomenon. But, in certain neonates, TSB levels may significantly increase, which could be a cause of concern due to the neurotoxic nature of UCB which may lead to lifelong neurologic outcome or even death. So, the appearance of neonatal jaundice commonly need diagnostic evaluation. The aim of this study was to evaluate the additional effect of UDCA in the resolution of indirect neonatal hyperbilirubinemia in neonates receiving phototherapy, hoping to decline the duration of phototherapy and hospitalization. This randomized controlled study was conducted upon 120 full term neonates, aged (1-7) days, birth weight of between 2500-4000 g, and were diagnosed as indirect neonatal hyperbilirubinemia. They admitted to NICU of Tanta University Hospital and of Menoufia University Hospital from (May 2017 to March 2019). All of them were suffering from indirect hyperbilirubinemia (40 ABO incompatibility and 20 Rh incompatibility and 60 exaggerated physiological jaundice). All of them received phototherapy according to their TSB level. These neonates were randomly allocated into four groups: Intervention groups: [administered oral 10 mg/kg/day of Ursodeoxycholic acid (UDCA). divided into two doses every 12 h]. group A: included 30 neonates with (non-hemolytic) indirect hyperbilirubinemia undergoing phototherapy and receiving UDCA. group B: included 30 neonates with (isoimmune hemolytic) indirect hyperbilirubinemia undergoing phototherapy and receiving UDCA.